Actively Recruiting

Phase 2
Phase 3
Age: 40Years - 85Years
All Genders
NCT06976268

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Led by Biohaven Therapeutics Ltd. · Updated on 2026-01-14

550

Participants Needed

15

Research Sites

118 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

CONDITIONS

Official Title

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

Who Can Participate

Age: 40Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female participants 40 to 85 years of age, inclusive, at the time of informed consent
  • Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society Clinical Diagnostic Criteria for PD
  • Have a clinician-documented diagnosis of idiopathic Parkinson's disease with onset within 2 years of the Screening Visit
Not Eligible

You will not qualify if you...

  • Medical history indicating a Parkinsonian syndrome other than idiopathic Parkinson's disease, including progressive supranuclear gaze palsy, multiple system atrophy, drug-induced Parkinsonism, essential tremor, or primary dystonia
  • Diagnosis of clinically significant central nervous system disease other than Parkinson's disease
  • Current smokers of any form, including tobacco smoke and electronic cigarettes
  • Treatment with Parkinson's disease medication(s)
  • Any other condition that may compromise participant safety, interfere with study conduct, or affect interpretation of study results, as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Site-049

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

Site-041

Los Angeles, California, United States, 90033

Actively Recruiting

3

Site-031

Farmington, Connecticut, United States, 06030

Actively Recruiting

4

Site-028

New Haven, Connecticut, United States, 06510

Actively Recruiting

5

Site-038

Atlantis, Florida, United States, 33462

Actively Recruiting

6

Site-017

Boca Raton, Florida, United States, 33486

Actively Recruiting

7

Site-051

Maitland, Florida, United States, 32751

Actively Recruiting

8

Site-027

Chicago, Illinois, United States, 60611

Actively Recruiting

9

Site-071

Boston, Massachusetts, United States, 02114

Actively Recruiting

10

Site-015

Farmington Hills, Michigan, United States, 48334

Actively Recruiting

11

Site-044

Chesterfield, Missouri, United States, 63005

Actively Recruiting

12

Site-005

New York, New York, United States, 10021

Actively Recruiting

13

Site-091

Portland, Oregon, United States, 97210

Actively Recruiting

14

Site-043

Round Rock, Texas, United States, 78681

Actively Recruiting

15

Site-007

Bellevue, Washington, United States, 98007

Actively Recruiting

Loading map...

Research Team

C

Chief Medical Officer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | DecenTrialz